Abstract:Abstract Background Inflammation plays an important role in the pathogenesis of Parkinson's disease (PD) through over-activation of microglia, which consequently causes the excessive production of proinflammatory and neurotoxic factors, and impacts surrounding neurons and eventually induces neurodegeneration. Hence, prevention of microglial over-activation has been shown to be a prime target for the development of therapeutic agents for inflammation-mediated neurodegenerative diseases. Methods For in vitro studies, mesencephalic neuron-glia cultures and reconstituted cultures were used to investigate the molecular mechanism by which FLZ, a squamosamide derivative, mediates anti-inflammatory and neuroprotective effects in both lipopolysaccharide-(LPS)- and 1-methyl-4-phenylpyridinium-(MPP+)-mediated models of PD. For in vivo studies, a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-(MPTP-) induced PD mouse model was used. Results FLZ showed potent efficacy in protecting dopaminergic (DA) neurons against LPS-induced neurotoxicity, as shown in rat and mouse primary mesencephalic neuronal-glial cultures by DA uptake and tyrosine hydroxylase (TH) immunohistochemical results. The neuroprotective effect of FLZ was attributed to a reduction in LPS-induced microglial production of proinflammatory factors such as superoxide, tumor necrosis factor-α (TNF-α), nitric oxide (NO) and prostaglandin E2 (PGE2). Mechanistic studies revealed that the anti-inflammatory properties of FLZ were mediated through inhibition of NADPH oxidase (PHOX), the key microglial superoxide-producing enzyme. A critical role for PHOX in FLZ-elicited neuroprotection was further supported by the findings that 1) FLZ's protective effect was reduced in cultures from PHOX-/- mice, and 2) FLZ inhibited LPS-induced translocation of the cytosolic subunit of p47PHOX to the membrane and thus inhibited the activation of PHOX. The neuroprotective effect of FLZ demonstrated in primary neuronal-glial cultures was further substantiated by an in vivo study, which showed that FLZ significantly protected against MPTP-induced DA neuronal loss, microglial activation and behavioral changes. Conclusion Taken together, our results clearly demonstrate that FLZ is effective in protecting against LPS- and MPTP-induced neurotoxicity, and the mechanism of this protection appears to be due, at least in part, to inhibition of PHOX activity and to prevention of microglial activation.

Fluoxetine Protects Neurons Against Microglial Activation-Mediated Neurotoxicity

Fluoxetine-mediated Inhibition of Endoplasmic Reticulum Stress is Involved in the Neuroprotective Effects of Parkinson's Disease

Squamosamide Derivative FLZ Protects Dopaminergic Neurons Against Inflammation-Mediated Neurodegeneration Through the Inhibition of NADPH Oxidase Activity

Fluoxetine Protects Against Inflammation and Promotes Autophagy in Mice Model of Post-Traumatic Stress Disorder.

Anti-inflammatory Effects of Fluoxetine in Lipopolysaccharide(lps)-Stimulated Microglial Cells

Fluoxetine Suppresses Inflammatory Reaction in Microglia under OGD/R Challenge Via Modulation of NF-κB Signaling

Fluoxetine Mitigating Late-Stage Cognition and Neurobehavior Impairment Induced by Cerebral Ischemia Reperfusion Injury Through Inhibiting ERS-mediated Neurons Apoptosis in the Hippocampus

Fluoxetine-enhanced autophagy ameliorates early brain injury via inhibition of NLRP3 inflammasome activation following subarachnoid hemorrhage in rats

Neuroprotective Role of Amentoflavone on LPS-Induced Parkinson's Disease Animal Model Via Inhibition of Microglia-Mediated Inflammation

Resveratrol Protects Dopamine Neurons Against Lipopolysaccharide-Induced Neurotoxicity Through Its Anti-Inflammatory Actions

Involvement of PI3K/Akt/FoxO3a and PKA/CREB Signaling Pathways in the Protective Effect of Fluoxetine Against Corticosterone-Induced Cytotoxicity in PC12 Cells

Fluoxetine is Neuroprotective in Early Brain Injury Via Its Anti-inflammatory and Anti-apoptotic Effects in a Rat Experimental Subarachnoid Hemorrhage Model

Neuroprotection of Fluoxetine Against Methylglyoxal Induced Lesion in Cultured Hippocampal Neurons

Fluoxetine upregulates phosphorylated-AKT and phosphorylated-ERK1/2 proteins in neural stem cells: evidence for a crosstalk between AKT and ERK1/2 pathways

FTY720 Inhibits MPP+-Induced Microglial Activation by Affecting NLRP3 Inflammasome Activation

Dextromethorphan Protects Dopaminergic Neurons Against Inflammation-Mediated Degeneration Through Inhibition of Microglial Activation

Clozapine Protects Dopaminergic Neurons from Inflammation-Induced Damage by Inhibiting Microglial Overactivation

Paeoniflorin Alleviates Neuroinflammatory Response by Suppressing HMGB1/RAGE Pathway Activation in MPTP Induced Mouse PD Model

Fluoxetine inhibited the activation of A1 reactive astrocyte in a mouse model of major depressive disorder through astrocytic 5-HT2BR/β-arrestin2 pathway

Fluoxetine ameliorates cognitive impairments induced by chronic cerebral hypoperfusion via down-regulation of HCN2 surface expression in the hippocampal CA1 area in rats

Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult